Canada: Intellectual Property

Canada's federal government and common law provinces lack a general 'right of publicity' protecting personality rights as property. This article examines the limited statutory provisions covering personality rights in Canada, with Quebec as a notable exception under civil law jurisdiction.

For manufacturers, defence-sector growth can be a significant opportunity. It can also require key decisions about capital, contracts, financing, and risk that affect the long-term strength of the business.

The efficiency gains are substantial, but so are the risks. Critical questions about who qualifies as an inventor, whether an AI-assisted invention is patentable, and what documentation companies need to protect...

Franchisees play a crucial role in protecting franchise brands, but how exactly do they help maintain trademark rights? This article explores the legal requirements for trademark...

Starting July 20, 2026, the USPTO will require Canadian patent applicants and owners to use US registered patent practitioners for most patent matters. Canadian patent agents and lawyers already registered before the USPTO remain qualified to represent Canadian applicants, allowing coordination of North American patent strategy through a single team. Canadian applicants currently filing directly or through unregistered representatives should review their upcoming deadlines and ensure appropriate representat

The Canadian Intellectual Property Office has released findings from roundtable discussions with 53 small and medium-sized businesses across six cities, revealing significant challenges in protecting intellectual property. Business owners identified cost, slow timelines, complexity, and limited knowledge as major barriers to accessing IP protection in Canada. CIPO plans to use this feedback to shape its upcoming business strategy and has already initiated a review of its fee structure.

The Supreme Court of Canada has released its highly anticipated decision in Pharmascience Inc. v. Janssen Inc.1, upholding the validity of Janssen’s patent for a long-acting dosing regimen for the treatment...

The Supreme Court of Canada has issued its most significant ruling on medical treatment patents in over fifty years, addressing whether dosing-regimen claims for schizophrenia medication constitute unpatentable methods of medical treatment. The 7-2 decision establishes a new framework for evaluating pharmaceutical patents, focusing on whether implementing the claimed invention requires professional medical skill and judgment. This landmark case provides crucial guidance for life sciences companies seeking p

La Cour suprême du Canada a rendu une décision historique confirmant que les méthodes de traitement médical demeurent non brevetables lorsqu'elles monopolisent la compétence et le jugement professionnels des médecins.

Canada's federal government and common law provinces lack a general 'right of publicity' protecting personality rights as property. This article examines the limited statutory provisions covering personality rights in Canada, with Quebec as a notable exception under civil law jurisdiction.

This website uses cookies to enhance user experience, monitor site usage, and manage traffic analytics. By continuing to browse, visitors consent to the cookie policy detailed in the site's privacy documentation.

Critical Minerals are playing an increasingly important role in the Canadian economy, not only as a significant income generator or, undeniably, from a defence standpoint...